Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02314858 · ClinicalTrials.gov registry record · NA
Tailored Treatment to Enhance Risk Perception in Sleep Apnea
A NA study, sponsored by National Jewish Health.
- Completed
- Registry status
- NA
- Development phase
- 284
- Enrollment target
NCT02314858: Completed NA study, sponsored by National Jewish Health.
NCT02314858 is a NA study that has completed, run by National Jewish Health. The registered enrollment target is 284 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02314858, a NA study, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 284 participants
- Enrollment target
Study Summary
Obstructive Sleep Apnea (OSA) is seen in approximately 6% of Americans. It is a serious medical condition with significant medical and psychological consequences, including diabetes, hypertension, and cardiovascular disease. The treatment of choice for OSA is Positive Airway Pressure therapy (PAP). PAP supplies positive pressure to the upper airway creating a "pneumatic splint" to keep the airway open during sleep. Adherence to PAP is notoriously low, with as few as 50% reaching minimal guidelines for adherence. One comprehensive review of adherence research found that adherence to PAP was less than that for any other medical disorder. The problem of adherence is significant not only because of the medical consequences that can ensue, but also because third party payers have begun to refuse to pay for PAP therapy when adherence is less than optimal, even in the face of clinical improvement. This is a critical time to address this problem. This research study is designed to identify methods that may help people respond to PAP, the most common therapy for OSA. Identifying these methods may be an important way to better care for patients with obstructive sleep apnea. With this research, the investigators hope to find ways to help people have a better response to treatment and a better quality of life.
Primary Outcome
Treatment adherence as measured directly from the participant's PAP device. Adherence is monitored objectively as time at prescribed pressure and daily measures of adherence are transmitted remotely to the study site nightly using a wireless modem. There are several specific adherence measures that will be available from the PAP units. These include the average hours of use per night across all nights, the average hours of use on nights PAP is actually used, and the percentage of nights PAP is u
Interventions
- BEHAVIORAL Treatment as Usual (TAU)
- BEHAVIORAL Brief Personalized Video (BPV)
- BEHAVIORAL Non-Personalized Video (NPV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2014-10-01 |
| Est. Completion | 2021-03 |
| Phase | NA |
What the finished NCT02314858 record still lists
NCT02314858 is an interventional study that assigns participants to a tested intervention. The registered 284 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 3 interventions - of which Treatment as Usual (TAU) is the first listed.
NCT02314858 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02314858 about?
NCT02314858 is a clinical study titled "Tailored Treatment to Enhance Risk Perception in Sleep Apnea". Obstructive Sleep Apnea (OSA) is seen in approximately 6% of Americans. It is a serious medical condition with significant medical and psychological consequences, including diabetes, hypertension, and cardiovascular disease. The treatment of choice for OSA is Positive Airway Pressure therapy (PAP). ...
What is the current status of trial NCT02314858?
This trial is currently completed. It is a NA study. The enrollment target is 284 participants. The study started on 2014-10-01. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02314858?
The interventions under investigation include: Treatment as Usual (TAU) (BEHAVIORAL), Brief Personalized Video (BPV) (BEHAVIORAL), Non-Personalized Video (NPV) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02314858?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02314858's enrollment target sits among peer trials
284 377th of 2000 higher than 1,623 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05263206 · 284 participants · Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- NCT05769218 · 284 participants · NA
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
- NCT06856577 · 284 participants · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
- NCT06963034 · 284 participants · Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI